Inmune bio, inc. (INMB)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-7,847

-7,678

-7,240

-5,712

-11,494

-12,440

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Net cash used in operating activities:
Stock-based compensation

3,803

4,096

3,878

3,883

8,514

10,001

0

0

0

Changes in operating assets and liabilities:
Research and development tax credit receivable

107

-24

629

581

444

485

0

0

0

Other tax receivable

-94

39

78

56

109

-74

0

0

0

Joint development cost receivable

-

17

2

-49

-23

91

0

0

0

Prepaid expenses

71

82

74

-50

170

-27

0

0

0

Prepaid expenses - related party

-81

26

7

198

-26

-158

0

0

0

Accounts payable and accrued liabilities

316

-151

147

27

192

426

0

0

0

Accounts payable and accrued liabilities - related parties

217

19

140

284

91

87

0

0

0

Deferred grant

0

-

-

-

0

-

-

-

-

Operating lease liability - related party

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-5,031

-5,384

-5,413

-3,917

-3,117

-2,058

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock

5,960

12,209

12,209

12,209

7,251

900

0

0

0

Purchase of common stock

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

4,948

12,209

12,209

12,209

7,251

900

0

0

0

Impact on cash from foreign currency translation

-35

-15

-63

-35

-40

-25

0

0

0

NET (DECREASE) INCREASE IN CASH

-118

6,809

6,731

8,255

4,092

-1,184

0

0

0

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes

-

-

-

-

-

-

-

0

0

Cash paid for interest expense

-

-

-

-

-

-

-

0

0

NONCASH INVESTING AND FINANCING ACTIVITIES:
Capital contribution

0

-

-

-

-

-

-

-

-

Issuance of warrants to placement agents

-

247

0

0

0

-

-

-

-